ICON Public Limited Company operates as a global clinical research organization (CRO), delivering outsourced development and commercialization services across Ireland, continental Europe, the United States, and various other international regions. The firm excels in the strategic design, execution, and analytical oversight of programs that facilitate the entire spectrum of clinical trials, from initial compound identification through all phases (I-IV) of human studies. Its comprehensive suite of clinical development offerings encompasses early-stage drug development, strategies for patient enrollment and retention, strategic planning and data analysis, late-phase investigations, cutting-edge data and technology platforms, and expert consulting. Additionally, ICON provides specialized medical imaging, clinical research, and laboratory services; meticulous project management; efficient site monitoring and administration; robust data management; biostatistical analysis and programming; professional medical writing and publication support; medical affairs expertise; independent endpoint adjudication and data monitoring committee services; vigilant pharmacovigilance; interactive response technologies (IRT); streamlined clinical supplies logistics; strategic regulatory guidance; impactful medical communication; and broad advisory services. ICON's diverse clientele includes companies across the pharmaceutical, biotechnology, and medical device sectors, alongside governmental and public health bodies. Established in 1990, the company maintains its headquarters in Dublin, Ireland.
